Stryker Management

Management criteria checks 3/4

Stryker's CEO is Kevin Lobo, appointed in Oct 2012, has a tenure of 11.5 years. total yearly compensation is $20.77M, comprised of 6.7% salary and 93.3% bonuses, including company stock and options. directly owns 0.026% of the company’s shares, worth €31.57M. The average tenure of the management team and the board of directors is 5.6 years and 6.7 years respectively.

Key information

Kevin Lobo

Chief executive officer

US$20.8m

Total compensation

CEO salary percentage	6.7%
CEO tenure	11.5yrs
CEO ownership	0.03%
Management average tenure	5.6yrs
Board average tenure	6.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Kevin Lobo's remuneration changed compared to Stryker's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$21m	US$1m	US$3b
Sep 30 2023	n/a	n/a	US$3b
Jun 30 2023	n/a	n/a	US$3b
Mar 31 2023	n/a	n/a	US$3b
Dec 31 2022	US$19m	US$1m	US$2b
Sep 30 2022	n/a	n/a	US$2b
Jun 30 2022	n/a	n/a	US$2b
Mar 31 2022	n/a	n/a	US$2b
Dec 31 2021	US$16m	US$1m	US$2b
Sep 30 2021	n/a	n/a	US$2b
Jun 30 2021	n/a	n/a	US$2b
Mar 31 2021	n/a	n/a	US$1b
Dec 31 2020	US$13m	US$1m	US$2b
Sep 30 2020	n/a	n/a	US$2b
Jun 30 2020	n/a	n/a	US$2b
Mar 31 2020	n/a	n/a	US$2b
Dec 31 2019	US$15m	US$1m	US$2b
Sep 30 2019	n/a	n/a	US$3b
Jun 30 2019	n/a	n/a	US$4b
Mar 31 2019	n/a	n/a	US$4b
Dec 31 2018	US$14m	US$1m	US$4b
Sep 30 2018	n/a	n/a	US$1b
Jun 30 2018	n/a	n/a	US$1b
Mar 31 2018	n/a	n/a	US$1b
Dec 31 2017	US$14m	US$1m	US$1b

Compensation vs Market: Kevin's total compensation ($USD20.77M) is above average for companies of similar size in the German market ($USD5.66M).

Compensation vs Earnings: Kevin's compensation has been consistent with company performance over the past year.

CEO

Kevin Lobo (58 yo)

11.5yrs

Tenure

US$20,767,847

Compensation

Mr. Kevin A. Lobo has been the Chief Executive Officer of Stryker Corporation since October 1, 2012 and serves as its President since October 01, 2021. He serves as Chairman of the Board at The Advanced Me...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Kevin Lobo	Chairman	11.5yrs	US$20.77m	0.026% $ 31.6m
Glenn Boehnlein	VP & CFO	8yrs	US$6.84m	0.0068% $ 8.1m
Viju Menon	Group President of Global Quality & Operations	6yrs	US$4.47m	0.0024% $ 2.9m
J. Pierce	Group President of MedSurg & Neurotechnology	5.7yrs	US$6.49m	0.015% $ 18.1m
Spencer Stiles	Group President of Orthopaedics & Spine	5.7yrs	US$6.49m	0.014% $ 16.4m
William Berry	VP & Chief Accounting Officer	2.7yrs	no data	0.00069% $ 823.2k
Robert Cohen	CTO and VP of Global R&D - Joint Replacement	no data	no data	no data
Alan Douville	VP, Chief Information Officer & Chief Information Security Officer	5.6yrs	no data	no data
Jason Beach	Vice President of Finance & Investor Relations	1.8yrs	no data	no data
Robert Fletcher	VP & Chief Legal Officer	5yrs	US$2.24m	0.0025% $ 3.0m
Dana McMahon	VP & Chief Compliance Officer	no data	no data	no data
Yin Becker	VP of Communications	5.3yrs	no data	0.0083% $ 9.9m

5.6yrs

Average Tenure

56yo

Average Age

Experienced Management: SYK's management team is seasoned and experienced (5.6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Kevin Lobo	Chairman	11.5yrs	US$20.77m	0.026% $ 31.6m
Lisa Skeete Tatum	Independent Director	3.9yrs	US$319.25k	0.00040% $ 477.2k
Howard Cox	Director Emeritus	5.9yrs	US$38.86k	no data
John Brown	Chairman Emeritus	no data	US$286.99k	5.27% $ 6.3b
Ronda Stryker	Independent Director	40.3yrs	US$322.74k	4.95% $ 5.9b
Mary Brainerd	Independent Director	6.7yrs	US$332.59k	0.0013% $ 1.6m
Srikant T. Datar	Independent Director	14.8yrs	US$319.25k	0.0084% $ 10.0m
Allan Golston	Independent Director	13.3yrs	US$334.25k	0.0031% $ 3.7m
Sherilyn S. McCoy	Lead Independent Director	5.9yrs	US$354.16k	0.00022% $ 262.5k
Rajeev Suri	Independent Director	5.9yrs	US$319.25k	0.0012% $ 1.4m
Giovanni Caforio	Independent Director	3.3yrs	US$319.25k	0.00040% $ 477.2k
Andrew Silvernail	Independent Director	10.4yrs	US$342.74k	0.0015% $ 1.7m

6.7yrs

Average Tenure

61.5yo

Average Age

Experienced Board: SYK's board of directors are considered experienced (6.7 years average tenure).

Stryker Management

Management criteria checks 3/4

Key information

Recent management updates

Independent Director recently sold €93m worth of stock

Insufficient new directors

Stryker Corporation, Annual General Meeting, May 09, 2024

Stryker Corporation Announces Dr. Srikant Datar Will Retire from Board of Directors

Key Executive recently sold €1.3m worth of stock

Independent Director recently sold €130k worth of stock

Recent updates

Stryker Corporation to Report Q1, 2024 Results on Apr 30, 2024

Stryker Launches Gamma4 Hip Fracture Nailing System in Europe

Upcoming dividend of US$0.80 per share

Fourth quarter dividend of US$0.80 announced

New minor risk - Insider selling

Independent Director recently sold €93m worth of stock

Stryker Announces the Launch of Prophecy Footprint, an Expansion of the Prophecy Surgical Planning System, Offering Comprehensive Surgical Planning Across the Entire Foot

Full year 2023 earnings released: EPS: US$8.34 (vs US$6.24 in FY 2022)

Stryker Corporation Provides Earnings Guidance for the Year 2024

Insufficient new directors

Upcoming dividend of US$0.80 per share at 1.0% yield

Stryker Corporation (NYSE:SYK) executed a binding offer to acquire Serf from SAS Menix.

Stryker Corporation, Annual General Meeting, May 09, 2024

Stryker Corporation Announces Dr. Srikant Datar Will Retire from Board of Directors

Stryker Corporation Declares Quarterly Dividend, Payable on January 31, 2024

Stryker Corporation Provides Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings released: EPS: US$1.82 (vs US$2.16 in 3Q 2022)

Stryker to Showcase Q Guidance System with Spine Guidance Software

Stryker Corporation to Report Q3, 2023 Results on Nov 02, 2023

Upcoming dividend of US$0.75 per share at 1.0% yield

Stryker Launches PROstep® MIS Lapidus, a New Minimally Invasive Surgical Option for Treating Patients with Bunions

Stryker Corporation Releases Its Next-Generation of Advanced Surgical Cameras

Stryker’S Pangea Systems Receive Food & Drug Administration Clearance

Key Executive recently sold €1.3m worth of stock

Stryker Corporation Provides Earnings Guidance for the Year 2023

Second quarter 2023 earnings released: EPS: US$1.94 (vs US$1.73 in 2Q 2022)

Stryker Corporation to Report Q2, 2023 Results on Aug 03, 2023

Upcoming dividend of US$0.75 per share at 1.0% yield

Independent Director recently sold €130k worth of stock

Surgeons Successfully Complete First Surgical Cases Using Stryker’s Q Guidance System with Cranial Guidance Software

Independent Director recently sold €266k worth of stock

Stryker Corporation Declares Quarter Dividend, Payable on July 31, 2023

First quarter 2023 earnings released: EPS: US$1.56 (vs US$0.85 in 1Q 2022)

Upcoming dividend of US$0.75 per share at 1.1% yield

Stryker’s Q Guidance System for Cranial Applications Receives FDA Clearance

Stryker Declares Quarterly Dividend, Payable on April 28, 2023

VP & CFO recently sold €6.2m worth of stock

Full year 2022 earnings released: EPS: US$6.24 (vs US$5.29 in FY 2021)

Stryker Corporation Provides Earnings Guidance for the Year 2023

Stryker Corporation to Report Q4, 2022 Results on Jan 31, 2023

Upcoming dividend of US$0.75 per share

Stryker Launches Citrefix™ Suture Anchor System

Stryker Corporation Declares Quarterly Dividend, Payable January 31, 2023

Independent Director recently sold €64k worth of stock

Stryker Opens the OR of the Future for Customers to Experience Tomorrow's OR

Insider recently sold €76k worth of stock

Third quarter 2022 earnings released: EPS: US$2.16 (vs US$1.16 in 3Q 2021)

Stryker Corporation Provides Earnings Guidance for the Year 2022

Stryker Corporation Launches Monterey AI Interbody System with New Pre-Clinical Data

Stryker Launches Q Guidance System with Spine Guidance Software

Upcoming dividend of US$0.69 per share

Stryker Receives FDA Clearance for OptaBlate Bone Tumor Ablation System

Stryker Launches Pulse Intelligent Delivery Platform

Stryker Launches New Gamma4 Hip Fracture Nailing System

Stryker Declares Quarterly Dividend, Payable on October 31, 2022

Stryker Corporation Provides Earnings Guidance for the Full Year of 2022

Second quarter 2022 earnings released: EPS: US$1.73 (vs US$1.57 in 2Q 2021)

Stryker Corporation to Report Q2, 2022 Results on Jul 26, 2022

Upcoming dividend of US$0.69 per share

Lieff Cabraser & Shavitz Law Group Files Federal Collective and California Class Action Lawsuit Against Stryker Corporation for Failure to Pay Overtime Wages, Provide Meal and Rest Breaks, and Pay Business Expenses

Stryker Receives FDA Clearance for Q Guidance System for Spine Applications

Stryker Corporation Announces Board Changes

Stryker Corporation Declares Quarterly Dividend, Payable July 29, 2022

First quarter 2022 earnings released: EPS: US$0.85 (vs US$0.80 in 1Q 2021)

Stryker Corporation to Report Q1, 2022 Results on Apr 28, 2022

Upcoming dividend of US$0.69 per share

Investor sentiment improved over the past week

Stryker Launches PROstep™ MICA® SOLO Guide

Stryker Corporation (NYSE:SYK) completed the acquisition of Vocera Communications, Inc. (NYSE:VCRA).